Richard Bryan, MD
Rheumatology · Queensbury, NYNPI 1508952953
Payments from drug & device makers
Across 1,060 payments — averaging $255.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$188K
- Mallinckrodt Enterprises LLC$43K
- Amgen$14K
- Aurinia Pharma U.S., Inc.$7K
- AbbVie$5K
- Genentech USA, Inc.$5K
- plus $9K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 374 | $187,835 |
| Mallinckrodt Enterprises LLC | 80 | $42,580 |
| Amgen(2 entities) | 63 | $13,596 |
| Aurinia Pharma U.S., Inc. | 13 | $6,971 |
| AbbVie | 213 | $5,434 |
| Genentech USA, Inc. | 10 | $4,747 |
| Johnson & Johnson | 105 | $4,104 |
| AstraZeneca | 40 | $971 |
| Pfizer | 51 | $901 |
| UCB, Inc. | 35 | $841 |
| GSK | 26 | $659 |
| Janssen Scientific Affairs, LLC | 3 | $326 |
| Novartis | 11 | $253 |
| E.r. Squibb & Sons, L.L.C. | 4 | $233 |
| Organon | 6 | $144 |
| Genentech, Inc. | 1 | $127 |
| ANI Pharmaceuticals, Inc. | 5 | $119 |
| Sandoz | 2 | $62 |
| Lilly USA, LLC | 3 | $55 |
| Scilex Pharmaceuticals Inc. | 2 | $47 |
| Sanofi | 2 | $38 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $35 |
| Fresenius Kabi USA, LLC | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $25 |
| Boehringer Ingelheim | 1 | $25 |
| Fidia Pharma USA Inc. | 1 | $24 |
| Hikma Pharmaceuticals USA | 1 | $22 |
| Sobi, Inc | 1 | $19 |
| Antares Pharma, Inc. | 1 | $19 |
| Merck | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
How this compares
$270,297 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Queensbury
- Amit SaxenaNew York$6.7M
- Cynthia AranowManhasset$5.3M
- Richard FurieNew Hyde Park$4.3M
- Robert SpieraNew York$4.3M
- David GoddardBrooklyn$3.9M
- Laurie GlimcherNew York$3.9M
- Anca AskanaseNew York$3.5M
- Grace WrightNew York$3M
- Jose ScherNew York$2.7M
- Kostas BotsoglouCheektowaga$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.